Impact of long-term Xuezhikang therapy on cardiovascular events in high-risk patients with nonspecific, preexisting abnormal liver tests: A post-hoc analysis from Chinese Coronary Secondary Prevention Study (CCSPS)

Abstract

sudden cardiac death in childrenwith the congenital long-QT syndrome. Circulation 2008;117:2184–91. [9] JonsC,MossAJ,Goldenberg I, et al. Risk of fatal arrhythmicevents in longQTsyndrome patients after syncope. J Am Coll Cardiol 2010;55:783–8. [10] Schwartz PJ. The congenital long QT syndromes from genotype to phenotype: clinical implications. J Intern Med 2006;259:39–47. [11] Schwartz PJ. Pharmacological and non-pharmacological management of the congenital long QT syndrome: the rationale. Pharmacol Ther 2011;131:171–7. [12] RuanY, LiuN, Bloise R, et al. Gating properties of SCN5Amutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 2007;116:1137–44. [13] Benhorin J, Taub R, Goldmit M, et al. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation 2000;101:1698–706. [14] Etheridge SP, Sanatani S, Cohen MI, et al. Long QT syndrome in children in the era of implantable defibrillators. J Am Coll Cardiol 2007;50:1335–40. [15] Zareba W, Goldenberg I, Moss AJ, Daubert J, McNitt S, Polonsky S. Implantable cardioverter-defibrillator therapy by genotype in long QT syndrome patients. Heart Rhythm 2007;4(Suppl):S131. [16] Eckardt L, Probst V, Smits JP, et al. Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation 2005;111: 257–63. [17] Schwartz PJ, Spazzolini C, Priori SG, et al. Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator andwhat happens to them?: data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. Circulation 2010;122:1272–82. [18] Kaufman ES, McNitt S, Moss AJ, et al. Risk of death in the long QT syndromewhen a sibling has died. Heart Rhythm 2008;5:831–6. [19] Kimbrough J, Moss AJ, ZarebaW, et al. Clinical implications for affected parents and siblings of probands with long-QT syndrome. Circulation 2001;104:557–62. [20] Barsheshet A, Moss AJ, McNitt S, et al. Risk of syncope in family members who are genotype-negative for a family-associated long-QT syndrome mutation. Circ Cardiovasc Genet 2011;4:491–9. [21] Kron J, Herre J, Renfroe EG, et al. Leadand device-related complications in the antiarrhythmics versus implantable defibrillators trial. Am Heart J 2001;141:92–8. [22] Krahn AD, Lee DS, Birnie D, et al. Predictors of short-term complications after implantable cardioverter-defibrillator replacement: results from the Ontario ICD Database. Circ Arrhythm Electrophysiol 2011;4:136–42. [23] Dewland TA, Pellegrini CN, Wang Y, Marcus GM, Keung E, Varosy PD. Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry. J Am Coll Cardiol 2011;58:1007–13.